Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) (BLAST)
A Confirmatory Multicenter, Single-arm Study to Assess the Efficacy, Safety, and Tolerability of the BiTE® Antibody Blinatumomab in Adult Patients With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (BLAST)
Sponsor: Amgen Research (Munich) GmbH
Listed as NCT01207388, this PHASE2 trial focuses on B-cell Acute Lymphoblastic Leukemia and remains completed. Sponsored by Amgen Research (Munich) GmbH, it has been updated 9 times since 2010, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Mar 2019 — Mar 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Amgen Research (Munich) GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
A Coruña, Spain , Angers, France , Antwerp, Belgium , Badalona, Spain , Barcelona, Spain , Bergamo, Italy , Berlin, Germany , Besançon, France , Bialystok, Poland , Birmingham, United Kingdom and 62 more locations